Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Antabio","sponsor":"CARB-X","pharmaFlowCategory":"D","amount":"$4.4 million","upfrontCash":"Undisclosed","newsHeadline":"Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FRANCE","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Antabio","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"French Multidisciplinary Consortium ARPEGE Awarded Public Funding of Close To \u20ac9 Million to Fight Antibiotic Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Antabio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Antabio

    Menu

    Antabio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Antabio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital Infections

              Details:

              MEM-ANT3310 combines the well-known carbapenem meropenem (MEM) with ANT3310, a breakthrough serine-beta-lactamase (SBL) inhibitor.

              Lead Product(s): ANT3310,Meropenem

              Therapeutic Area: Infections and Infectious Diseases Product Name: MEM-ANT3310

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Antabio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              French Multidisciplinary Consortium ARPEGE Awarded Public Funding of Close To €9 Million to Fight Antibiotic Resistance

              Details:

              The funding for Antabio will allow to continue the development of ANT3310 towards clinical studies and reach crucial milestones such as the clinical demonstration of its safety and tolerability in humans.

              Lead Product(s): ANT3310,Meropenem

              Therapeutic Area: Infections and Infectious Diseases Product Name: ANT3310

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bpifrance

              Deal Size: $10.0 million Upfront Cash: Undisclosed

              Deal Type: Funding January 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Antabio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Antabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310

              Details:

              QIDP is granted to Antabio's MEM-ANT3310 for major hospital indications including nosocomial pneumonia.

              Lead Product(s): ANT3310,Meropenem

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Antabio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Antabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

              Details:

              The funding is to support the development of Antabio's novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: CARB-X

              Deal Size: $4.4 million Upfront Cash: Undisclosed

              Deal Type: Funding January 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY